249 related articles for article (PubMed ID: 31902694)
21. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
22. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
Bacher U; Haferlach T; Alpermann T; Zenger M; Hochhaus A; Beelen DW; Uppenkamp M; Rummel M; Kern W; Schnittger S; Haferlach C
Br J Haematol; 2011 Mar; 152(6):713-20. PubMed ID: 21275954
[TBL] [Abstract][Full Text] [Related]
23. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Neuendorff NR; Burmeister T; Dörken B; Westermann J
Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971
[TBL] [Abstract][Full Text] [Related]
25. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.
Preuner S; Mitterbauer G; Mannhalter C; Herndlhofer S; Sperr WR; Valent P; Lion T
Eur J Cancer; 2012 Jan; 48(2):233-6. PubMed ID: 21955823
[TBL] [Abstract][Full Text] [Related]
26. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.
Ikeda D; Chi S; Uchiyama S; Nakamura H; Guo YM; Yamauchi N; Yuda J; Minami Y
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682627
[TBL] [Abstract][Full Text] [Related]
27. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
28. t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression.
Tang G; Hu S; Wang SA; Xie W; Lin P; Xu J; Toruner G; Zhao M; Gu J; Doty M; Li S; Medeiros LJ; Tang Z
J Mol Diagn; 2019 Mar; 21(2):343-351. PubMed ID: 30576868
[TBL] [Abstract][Full Text] [Related]
29. Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Levato L; Gianfelici V; Caglioti F; Russo A; Giugliano E; Mannella A; Molica S
Chemotherapy; 2020; 65(1-2):51-53. PubMed ID: 32570264
[TBL] [Abstract][Full Text] [Related]
30. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
31. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
32. Concurrent
Salter B; Ge S; Tam A; Demczuk S; Butcher D; McCready E; Khalaf D
EJHaem; 2024 Jun; 5(3):607-615. PubMed ID: 38895060
[TBL] [Abstract][Full Text] [Related]
33. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
34. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
35. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
[TBL] [Abstract][Full Text] [Related]
36. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
37. A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia.
Peterson JF; Ketterling RP; Huang L; Finn LE; Shi M; Hoppman NL; Greipp PT; Baughn LB
Genes Chromosomes Cancer; 2019 Sep; 58(9):665-668. PubMed ID: 30790375
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Merz LE; Perissinotti AJ; Marini BL; Burke PW; Crouch A; Erba HP; Bixby D
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):24-30. PubMed ID: 31711889
[TBL] [Abstract][Full Text] [Related]
39. De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome.
Min X; Na Z; Yanan L; Chunrui L
J Hematol Oncol; 2011 Nov; 4():45. PubMed ID: 22075327
[TBL] [Abstract][Full Text] [Related]
40. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
